External organizationRoche Pharma AG

Basic data

Name:

Roche Pharma AG

Country:

Germany

Region/province:

Baden-Württemberg

City:

Grenzach-Wyhlen

URL:

http://www.roche.de/

Projects

A phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lamipalizumab administered intravitreally to patients with geographic atrophy secondary to age-related miacular degeneration

2015 - 2018

Roche Pharma AG

A Phase III, open-label, randomized Study of MPDL3280A (Anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma

2016 - 2020

Roche Pharma AG

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

2016 - 2020

Roche Pharma AG

ENSEMBLE – AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATETHE EFFECTIVENESS AND SAFETY OFOCRELIZUMAB IN PATIENTS WITH EARLY STAGERELAPSING REMITTING MULTIPLE SCLEROSIS

2017 - 2023

Roche Pharma AG

Toffife – Tocilizumab for the Treatment of Familial Mediterranean Fever

2017 - 2018

Roche Pharma AG

Chugai Pharma Europe Ltd.

Trilogy – A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION−POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA

2017 - 2019

Roche Pharma AG

Help

will be deleted permanently. This cannot be undone.